Analysts’ Viewpoint on Market Scenario
High rate of adoption of meningococcal vaccine can be ascribed to the rise in awareness about the treatment avenues of meningococcal meningitis. This rare disease can lead to serious complications; it has a high fatality rate when left untreated. This type of meningitis is spread through contact with respiratory droplets and may have asymptomatic carriers.
It also causes an infection in the lining of the brain as well as the spinal cord. Increase in number of ongoing clinical programs for meningococcal vaccines at various stages of development around the world provides significant opportunities for market participants.
Companies focusing on assessing the potential of existing meningococcal vaccines for expanded age indications are likely to consolidate their position in the market. Moreover, rise in marketing approvals around the world is driving the global market.
Meningococcal vaccines are used to prevent diseases such as meningitis, meningococcemia, and septicemia caused due to N. meningitides. Meningococcal disease, especially meningococcal meningitis, is highly infectious among individuals or communities.
Several meningococcal serogroups have been identified to date; of these, serogroups A, B, C, Y, and W-135 are the most prominent ones causing the infection.
Rise in prevalence of meningococcal meningitis has recently emerged as a public health concern. Several meningococcal infection treatment options are available around the world; however, the disease still claims several lives.
Meningococcal disease is spread through contact with secretions from the nose and throat (saliva or spit). Kissing, sharing silverware, drinking from the same container, sharing a cigarette or lipstick, coughing, and having close social contact (living in the same house) are examples of how the disease spreads. Vaccination is one of the most effective ways to prevent meningococcal disease.
Meningococcal disease is infrequent; however, it has a fatality rate between 5% and 15%. If left untreated, it frequently leads to serious complications. Meningococcal meningitis causes an infection of the brain and spinal cord lining. It has the potential to cause large epidemics and endemics.
Each year, approximately 10 to 15 of every 100 people infected with meningococcal disease die. One in every five survivors is likely to suffer from permanent disabilities such as deafness, brain damage, limb loss, or seizures. Hence, demand for meningitis vaccines is increasing around the globe.
The National Meningitis Association (NMA) encourages collaboration by offering opportunities to work with government agencies, corporations, and other non-profit organizations in order to raise awareness about meningococcal disease, its prevention, and the critical need for immediate treatment after diagnosis. Increase in coverage rate of immunization programs around the world is likely to increase access to vaccines.
The Meningitis Foundation of America (MFA) is a non-profit organization that provides information and support to people who suffer from meningitis. The foundation also aims to raise public and medical awareness about the early symptoms of meningitis. Thus, the meningococcal vaccines market is estimated to expand at a steady pace during the forecast period.
Based on type, the conjugate vaccine segment is projected to dominate the market and account for 62% share by 2031. The benefits of meningococcal conjugate vaccines, such as long-lasting immunity, immunologic memory, avidity, and herd immunity, are driving sales. This trend is expected to continue during the forecast period.
Conjugate vaccines are extensively used in mass vaccination campaigns in affected areas such as Africa. Moreover, they have the ability to increase antibody persistence.
Various meningococcal conjugate vaccine programs have been introduced around the world over the last few decades. The vaccine has significantly reduced the incidence of meningococcal disease since 2010.
The recently introduced serogroup C conjugate vaccine is safe and effective even in the youngest children. Vaccines against group B meningococci have shown modest efficacy in both children and adults.
North America dominated the global meningococcal vaccines market in 2021. The market in the region is anticipated to expand at a notable CAGR from 2022 to 2031. Government recommendations and support, and high R&D investments are driving the market in North America.
The U.S. is expected to be a prominent market for meningococcal vaccines in North America due to the rise in disease awareness and improved health care infrastructure in the country.
Meningococcal disease has been declining in the U.S. since the 1990s. According to the Centers for Disease Control and Prevention (CDC), approximately 350 cases of meningococcal disease were reported in 2017. Furthermore, awareness among the general public is increasing.
The meningococcal vaccines market in Asia Pacific is projected to grow at a rapid pace due to the presence of a large population, improved access to health care systems, and increase in awareness about the meningococcal disease in the region.
The global meningococcal vaccines market is fragmented, with a large number of large-scale vendors controlling a majority of the share. Most of the firms are investing significantly in comprehensive research and development activities.
Expansion of product portfolios and mergers and acquisitions are major strategies adopted by key players. Market players are focusing on key trends in meningococcal vaccines with the help of recent R&D insights.
Sanofi SA, Novartis International, GlaxoSmithKline plc, Pfizer Inc., Nuron Biotech, JN-International Medical Corporation, Serum Institute of India Ltd., Baxter International, and Biomed Pvt. Ltd. are the prominent entities operating in the market.
Each of these players has been profiled in the meningococcal vaccines market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 4.2 Bn |
|
Market Forecast Value in 2031 |
US$ 9.2 Bn |
|
Growth Rate (CAGR) |
9.4% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes cross segment analysis at global as well as regional level. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
It was valued at US$ 4.2 Bn in 2021
It is projected to reach US$ 9.2 Bn by 2031
It is anticipated to record a CAGR of 9.4% from 2022 to 2031
Growth in prevalence of meningitis, rise in disease awareness, and increase in marketing approvals are prominent trends driving the market
The conjugate vaccine type segment held over 60% share of the global market in 2021
North America is expected to hold a major share of the global market during the forecast period
Sanofi SA, Novartis International, GlaxoSmithKline plc, Pfizer Inc., Nuron Biotech, JN-International Medical Corporation, Serum Institute of India Ltd., Baxter International, and Biomed Pvt. Ltd
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Meningococcal Vaccines Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Meningococcal Vaccines Market Analysis and Forecast, 2021–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Regulatory Scenario by Region/globally
5.3. Covid-19 Impact analysis
6. Global Meningococcal Vaccines Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031
6.3.1. Polysaccharide
6.3.1.1. Menomune
6.3.1.2. Mencevax
6.3.1.3. NmVac4
6.3.1.4. Others
6.3.2. Conjugate Vaccines
6.3.2.1. Menactra
6.3.2.2. Menveo
6.3.2.3. NeisVac-C
6.3.2.4. Nimenrix
6.3.2.5. Others
6.3.3. Combination Vaccines
6.3.3.1. MenHibrix
6.3.3.2. Menitorix
6.3.4. Men B Vaccines
6.3.4.1. Bexsero
6.3.4.2. Trumenba
6.4. Global Meningococcal Vaccines Market Attractiveness, by Type
7. Global Meningococcal Vaccines Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031
7.3.1. Retail Pharmacies
7.3.2. Hospital Pharmacies
7.3.3. Others (online pharmacies, drug stores)
7.4. Global Meningococcal Vaccines Market Attractiveness, by End-user
8. Global Meningococcal Vaccines Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Meningococcal Vaccines Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Meningococcal Vaccines Market Attractiveness, by Country/Region
9. North America Meningococcal Vaccines Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031
9.2.1. Polysaccharide
9.2.1.1. Menomune
9.2.1.2. Mencevax
9.2.1.3. NmVac4
9.2.1.4. Others
9.2.2. Conjugate Vaccines
9.2.2.1. Menactra
9.2.2.2. Menveo
9.2.2.3. NeisVac-C
9.2.2.4. Nimenrix
9.2.2.5. Others
9.2.3. Combination Vaccines
9.2.3.1. MenHibrix
9.2.3.2. Menitorix
9.2.4. Men B Vaccines
9.2.4.1. Bexsero
9.2.4.2. Trumenba
9.3. North America Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031
9.3.1. Retail Pharmacies
9.3.2. Hospital Pharmacies
9.3.3. Others (online pharmacies, drug stores)
9.4. North America Meningococcal Vaccines Market Value Forecast, by Country, 2021–2031
9.4.1. U.S.
9.4.2. Canada
9.5. North America Meningococcal Vaccines Market Attractiveness Analysis
9.5.1. By Type
9.5.2. By End-user
9.5.3. By Country
10. Europe Meningococcal Vaccines Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031
10.2.1. Polysaccharide
10.2.1.1. Menomune
10.2.1.2. Mencevax
10.2.1.3. NmVac4
10.2.1.4. Others
10.2.2. Conjugate Vaccines
10.2.2.1. Menactra
10.2.2.2. Menveo
10.2.2.3. NeisVac-C
10.2.2.4. Nimenrix
10.2.2.5. Others
10.2.3. Combination Vaccines
10.2.3.1. MenHibrix
10.2.3.2. Menitorix
10.2.4. Men B Vaccines
10.2.4.1. Bexsero
10.2.4.2. Trumenba
10.3. Europe Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031
10.3.1. Retail Pharmacies
10.3.2. Hospital Pharmacies
10.3.3. Others (online pharmacies, drug stores)
10.4. Europe Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe Meningococcal Vaccines Market Attractiveness Analysis
10.5.1. By Type
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Meningococcal Vaccines Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031
11.2.1. Polysaccharide
11.2.1.1. Menomune
11.2.1.2. Mencevax
11.2.1.3. NmVac4
11.2.1.4. Others
11.2.2. Conjugate Vaccines
11.2.2.1. Menactra
11.2.2.2. Menveo
11.2.2.3. NeisVac-C
11.2.2.4. Nimenrix
11.2.2.5. Others
11.2.3. Combination Vaccines
11.2.3.1. MenHibrix
11.2.3.2. Menitorix
11.2.4. Men B Vaccines
11.2.4.1. Bexsero
11.2.4.2. Trumenba
11.3. Asia Pacific Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031
11.3.1. Retail Pharmacies
11.3.2. Hospital Pharmacies
11.3.3. Others (online pharmacies, drug stores)
11.4. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Meningococcal Vaccines Market Attractiveness Analysis
11.5.1. By Type
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Meningococcal Vaccines Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Latin America Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031
12.2.1. Polysaccharide
12.2.1.1. Menomune
12.2.1.2. Mencevax
12.2.1.3. NmVac4
12.2.1.4. Others
12.2.2. Conjugate Vaccines
12.2.2.1. Menactra
12.2.2.2. Menveo
12.2.2.3. NeisVac-C
12.2.2.4. Nimenrix
12.2.2.5. Others
12.2.3. Combination Vaccines
12.2.3.1. MenHibrix
12.2.3.2. Menitorix
12.2.4. Men B Vaccines
12.2.4.1. Bexsero
12.2.4.2. Trumenba
12.3. Latin America Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031
12.3.1. Retail Pharmacies
12.3.2. Hospital Pharmacies
12.3.3. Others (online pharmacies, drug stores)
12.4. Latin America Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Meningococcal Vaccines Market Attractiveness Analysis
12.5.1. By Type
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Meningococcal Vaccines Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031
13.2.1. Polysaccharide
13.2.1.1. Menomune
13.2.1.2. Mencevax
13.2.1.3. NmVac4
13.2.1.4. Others
13.2.2. Conjugate Vaccines
13.2.2.1. Menactra
13.2.2.2. Menveo
13.2.2.3. NeisVac-C
13.2.2.4. Nimenrix
13.2.2.5. Others
13.2.3. Combination Vaccines
13.2.3.1. MenHibrix
13.2.3.2. Menitorix
13.2.4. Men B Vaccines
13.2.4.1. Bexsero
13.2.4.2. Trumenba
13.3. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031
13.3.1. Retail Pharmacies
13.3.2. Hospital Pharmacies
13.3.3. Others (online pharmacies, drug stores)
13.4. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Meningococcal Vaccines Market Attractiveness Analysis
13.5.1. By Type
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2021
14.3. Company Profiles
14.3.1. Sanofi SA
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Strategic Overview
14.3.2. Novartis International
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Strategic Overview
14.3.3. GlaxoSmithKline plc
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Strategic Overview
14.3.4. Pfizer Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Strategic Overview
14.3.5. Nuron Biotech.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Strategic Overview
14.3.6. JN-International Medical Corporation.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Strategic Overview
14.3.7. Serum Institute of India Ltd
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Strategic Overview
14.3.8. Baxter International
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Strategic Overview
List of Tables
Table 01: Global Meningococcal Vaccine Market Pipeline Analysis
Table 02: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031
Table 03: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide Meningococcal Vaccines, 2022–2031
Table 04: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Meningococcal Vaccines, 2022–2031
Table 05: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Meningococcal Vaccines, 2022–2031
Table 06: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Meningococcal Vaccines, 2022–2031
Table 07: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031
Table 08: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Region, 2022–2031
Table 09: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country, 2022–2031
Table 10: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031
Table 11: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022–2031
Table 12: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022–2031
Table 13: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022–2031
Table 14: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022–2031
Table 15: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031
Table 16: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031
Table 17: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031
Table 18: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022–2031
Table 19: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022–2031
Table 20: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022–2031
Table 21: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022–2031
Table 22: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031
Table 23: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031
Table 24: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031
Table 25: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022–2031
Table 26: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022–2031
Table 27: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022–2031
Table 28: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022–2031
Table 29: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031
Table 30: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031
Table 31: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031
Table 32: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022–2031
Table 33: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022–2031
Table 34: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022–2031
Table 35: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022–2031
Table 36: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031
Table 37: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031
Table 38: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031
Table 39: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022–2031
Table 40: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022–2031
Table 41: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022–2031
Table 42: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022–2031
Table 43: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031
List of Figures
Figure 01: Global Meningococcal Vaccines Market Size (US$ Bn) and Distribution, by Region, 2022 and 2031
Figure 02: Market Snapshot of Global Meningococcal Vaccines Market
Figure 03: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022–2031
Figure 04: Market Value Share, by Type, 2021
Figure 05: Market Value Share, by End-user, 2021
Figure 06: Market Value Share, by Region, 2021
Figure 07: Global Meningococcal Vaccines Market Value Share Analysis, by Type, 2022 and 2031
Figure 08: Global Meningococcal Vaccines Market Attractiveness, by Type2022–2031
Figure 09: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Polysaccharide Vaccines, 2022–2031
Figure 10: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Conjugate Vaccines, 2022–2031
Figure 11: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, Combination Vaccines, 2022–2031
Figure 12: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Men B Vaccines, 2021
Figure 13: Global Meningococcal Vaccines Market Value Share Analysis, by End-user, 2022 and 2031
Figure 14: Global Meningococcal Vaccines Market Attractiveness, by End-user2022–2031
Figure 15: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2022–2031
Figure 16: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2022–2031
Figure 17: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2022–2031
Figure 18: Global Meningococcal Vaccines Market Value Share (%), by Region, 2022 and 2031
Figure 19: Global Meningococcal Vaccines Market Attractiveness, by Region2022–2031
Figure 20: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022–2031
Figure 21: North America Meningococcal Vaccines Market Value Share (%), by Country, 2022 and 2031
Figure 22: North America Meningococcal Vaccines Market Attractiveness, by Country2022–2031
Figure 23: North America Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031
Figure 24: North America Meningococcal Vaccines Market Attractiveness, by Type2022–2031
Figure 25: North America Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031
Figure 26: North America Meningococcal Vaccines Market Attractiveness, by End-user2022–2031
Figure 27: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022–2031
Figure 28: Europe Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2022 and 2031
Figure 29: Europe Meningococcal Vaccines Market Attractiveness, by Country/Sub-region2022–2031
Figure 30: Europe Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031
Figure 31: Europe Meningococcal Vaccines Market Attractiveness, by Type2022–2031
Figure 32: Europe Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031
Figure 33: Europe Meningococcal Vaccines Market Attractiveness, by End-user2022–2031
Figure 34: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022–2031
Figure 35: Asia Pacific Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2022 and 2031
Figure 36: Asia Pacific Meningococcal Vaccines Market Attractiveness, by Country/Sub-region2022–2031
Figure 37: Asia Pacific Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031
Figure 38: Asia Pacific Meningococcal Vaccines Market Attractiveness, by Type2022–2031
Figure 39: Asia Pacific Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031
Figure 40: Asia Pacific Meningococcal Vaccines Market Attractiveness, by End-user2022–2031
Figure 41: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022–2031
Figure 42: Latin America Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2022 and 2031
Figure 43: Latin America Meningococcal Vaccines Market Attractiveness, by Country/Sub-region2022–2031
Figure 44: Latin America Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031
Figure 45: Latin America Meningococcal Vaccines Market Attractiveness, by Type2022–2031
Figure 46: Latin America Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031
Figure 47: Latin America Meningococcal Vaccines Market Attractiveness, by End-user2022–2031
Figure 48: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022–2031
Figure 49: Middle East & Africa Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2022 and 2031
Figure 50: Middle East & Africa Meningococcal Vaccines Market Attractiveness, by Country/Sub-region2022–2031
Figure 51: Middle East & Africa Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031
Figure 52: Middle East & Africa Meningococcal Vaccines Market Attractiveness, by Type2022–2031
Figure 53: Middle East & Africa Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031
Figure 54: Middle East & Africa Meningococcal Vaccines Market Attractiveness, by End-user2022–2031
Figure 55: Global Meningococcal Vaccines Market Share, by Company, 2018
Figure 56: Baxter International, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2016–2018
Figure 57: Baxter International, Inc. Breakdown of Net Sales (%), by Region, 2018
Figure 58: Pfizer Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2016–2018
Figure 59: Pfizer Inc. Breakdown of Net Sales (%), by Region, 2018
Figure 60: Novartis AG Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2021
Figure 61: Novartis AG Breakdown of Net Sales, by Region, 2021
Figure 62: Novartis AG Breakdown of Net Sales, by Business Segment, 2021
Figure 63: Novartis AG Breakdown of Net Sales, by Innovative Medicines Business Units, 2021
Figure 64: Sanofi S.A Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2021
Figure 65: Sanofi S.A Breakdown of Net Sales (%), by Business Segment, 2021
Figure 66: GlaxoSmithKline plc Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2021
Figure 67: GlaxoSmithKline plc Breakdown of Net Sales (%), by Business Segment, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Meningococcal Vaccines Market
